Stockscreener 앱 받기
16.30
5.73%
-0.99
시간 외 거래:
16.30
전일 마감가:
$17.29
열려 있는:
$17.2
하루 거래량:
1.95M
Relative Volume:
1.19
시가총액:
$1.89B
수익:
$674.41M
순이익/손실:
$-173.05M
주가수익비율:
-10.62
EPS:
-1.5343
순현금흐름:
$-48.07M
1주 성능:
-5.23%
1개월 성능:
-2.10%
6개월 성능:
+13.59%
1년 성능:
-11.70%
1일 변동 폭
$16.01
$17.35
1주일 범위
$16.01
$18.08
52주 변동 폭
$9.82
$18.92
Novocure Ltd Stock (NVCR) Company Profile
명칭
Novocure Ltd
전화
44 (0)15 3475 6700
주소
NO. 4 THE FORUM, ST. HELIER
Compare NVCR vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
16.30 | 1.89B | 674.41M | -173.05M | -48.07M | -1.5343 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | 개시 | Ladenburg Thalmann | Buy |
| 2024-12-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-10-16 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-08-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | 개시 | SVB Securities | Outperform |
| 2023-07-31 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2023-06-07 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2023-05-16 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-01-06 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | 재확인 | H.C. Wainwright | Buy |
| 2022-11-29 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2022-05-16 | 개시 | H.C. Wainwright | Buy |
| 2022-02-08 | 개시 | Loop Capital | Buy |
| 2022-02-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-20 | 업그레이드 | Truist | Hold → Buy |
| 2022-01-03 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-07-01 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-14 | 다운그레이드 | Wedbush | Neutral → Underperform |
| 2021-01-25 | 재확인 | Piper Sandler | Overweight |
| 2020-09-23 | 개시 | Northland Capital | Outperform |
| 2020-09-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | 다운그레이드 | Truist | Buy → Hold |
| 2020-06-01 | 재개 | Oppenheimer | Perform |
| 2020-05-01 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-04-09 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2020-03-05 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-07-29 | 업그레이드 | SunTrust | Hold → Buy |
| 2019-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-07-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-03-20 | 개시 | SunTrust | Hold |
| 2018-11-02 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | 개시 | Evercore ISI | Outperform |
| 2018-04-18 | 재확인 | Mizuho | Buy |
| 2018-02-23 | 재확인 | Mizuho | Buy |
| 2017-05-24 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | 재확인 | Wedbush | Outperform |
| 2016-01-19 | 개시 | Barclays | Underweight |
| 2015-12-02 | 개시 | Deutsche Bank | Hold |
모두보기
Novocure Ltd 주식(NVCR)의 최신 뉴스
Does NovoCure’s Shift Into Russell Value Indexes Recast NVCR’s Core Investment Narrative? - simplywall.st
Price to book forward of NovoCure Ltd. – FWB:038 - TradingView
Price to earnings forward of NovoCure Ltd. – FWB:038 - TradingView
NVCR stock. NovoCure’s business case stays in view. - ad-hoc-news.de
Is NovoCure (NVCR) Cheap As TRIDENT Fallout Clouds Its Valuation? - simplywall.st
NVCRNovoCure Ltd Volatility & Greeks - Finviz
NovoCure (NVCR) CHRO acquires 1,905 discounted shares in ESPP purchase - Stock Titan
NovoCure (NVCR) CEO adds 1,905 shares through 2025 employee share purchase plan - Stock Titan
NovoCure (NVCR) General Counsel adds 1,299 ESPP shares to holdings - Stock Titan
NovoCure (NASDAQ: NVCR) director adds shares through 2025 employee stock purchase plan - Stock Titan
NovoCure's Cancer Treatment Device Option Pax Gets European Approval - Yahoo Finance
Novocure sets July 23 call for Q2 2026 results before markets open - Stock Titan
Novocure's Optune Pax Receives EU CE Mark for Pancreatic Cancer Treatment - GuruFocus
HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026? - AOL.com
symbol__ Stock Quote Price and Forecast - CNN
Novocure wins CE Mark for Optune Pax pancreatic cancer treatment - grafa.com
Novocure (NVCR) Gains CE Mark for New Pancreatic Cancer Treatmen - GuruFocus
Novocure receives CE Mark for pancreatic cancer device in Europe By Investing.com - Investing.com Nigeria
Novocure’s Optune Pax® Wins CE Mark for Pancreatic Cancer After Phase 3 Success in PANOVA-3 Trial - Minichart
Novocure receives CE Mark for pancreatic cancer device in Europe - Investing.com
Optune Pax CE Mark expands Novocure (NASDAQ: NVCR) pancreatic cancer reach - Stock Titan
Wearable pancreatic cancer device Optune Pax wins CE Mark in Europe - Stock Titan
NovoCure (NVCR) Is Up 8.1% After TRIDENT Shows No Survival Gain From Earlier TTFields Start - Sahm
NovoCure Ltd. Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh - TradingView
NovoCure (NVCR) Could Be 42% Undervalued On Mixed TRIDENT Trial Results - simplywall.st
NovoCure Ltd. Actuals & Estimates (NASDAQ:NVCR) - TradingView
NovoCure Ltd. Actuals & Estimates (LSX:A140ML) - TradingView
NVCR Forecast — Price Target — Prediction for 2027 - TradingView
2026-06-23 | Bronstein, Gewirtz & Grossman, LLC Encourages NovoCure Limited (NVCR) Investors to Inquire about Securities Investigation | NDAQ:NVCR | Press Release - Stockhouse
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $46 - Moomoo
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026? - Yahoo Finance
NovoCure StockSunday background on TTFields cancer therapy specialist - AD HOC NEWS
NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm - Business Wire
NovoCure (NVCR) Is Down 19.7% After TRIDENT Misses Survival Endpoint In Earlier TTFields Use - simplywall.st
NovoCure (NVCR) Stock Could Be 31.5% Undervalued After TRIDENT Trial Result - Sahm
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026? - Yahoo Finance
FreeCast surges premarket; Accenture, Novocure slide By Investing.com - Investing.com Canada
Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR) - Moomoo
Novocure (NVCR) Experiences Significant Decline in Stock Price - GuruFocus
NVCR Reiterated by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Novocure’s Optune Gio fails to show benefit at earlier stage - Yahoo Finance
Novocure TRIDENT trial misses primary endpoint - grafa.com
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $46 - Moomoo
Novocure (NVCR) Reports TRIDENT Trial Results for Glioblastoma T - GuruFocus
Novocure Announces Topline Phase 3 TRIDENT Trial Data for TTFields Therapy in Newly Diagnosed Glioblastoma Patients – Minichart - Minichart
Novocure (NVCR) Faces 20% Drop After Phase 3 Trial Setback - GuruFocus
Novocure (NVCR) Sees Significant Decline in Stock Price - GuruFocus
Novocure Brain Cancer Study Shows No Significant Survival Benefit, Stock Tanks - Benzinga
Novocure Shares Slide After Phase 3 Glioblastoma Study Falls Short of Survival Goal - Yahoo Finance
Novocure device fails to improve brain cancer patients’ survival in phase 3 test - Fierce Biotech
Novocure Ltd (NVCR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Novocure Ltd (NVCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.36%
자본화:
|
볼륨(24시간):